Skip to main content
Drug Profiles/Updates, FDA Updates
Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Online First
Drug Profiles/Updates
FDA Approves Bridion to Reverse Effects of Neuromuscular Blocking Drugs Used During Surgery
Drug Profiles/Updates
Concise Review of Obinutuzumab in the Treatment of Patients with Chronic Lymphocytic Leukemia
Peter Tang, PharmD Candidate, Tristan Lindfelt, PharmD, BCPS, BCACP, BCOP, Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Drug Profiles/Updates
Omacetaxine Mepesuccinate: A Novel mRNA Translation Inhibitor for Drug-Resistant Chronic Myelogenous Leukemia
Jacqueline L. Olin, MS, PharmD, BCPS, Sabrina W. Cole, PharmD, BCPS, Amie J. Dirks-Naylor, PhD
Drug Profiles/Updates
FLAG-IDA Regimen-Induced Thrombotic Microangiopathy: A Case Report
Juan Montoro, MD, Montserrat Gomez, MD, Mar Tomo, MD PhD, Teresa Torrecillas, PhD
Drug Profiles/Updates
The Effect of Atazanavir on Doxorubicin Pharmacokinetics: A Case Report
Neha Umesh Sheth, PharmD, AAHIVP, BCPS, Steven Gilmore, PharmD, BCOP, Kenneth S. Bauer Jr, PharmD, PhD, Saranya Chumsri, MD
Drug Profiles/Updates
Palifermin Use for the Prevention of Chemotherapy-Induced Oral Mucositis in Anal Cancer: A Case Report
Amanda Brahim, PharmD, BCPS, Mohammed Ibrahim, PharmD, CRPH, BCOP, BCPS, Tim Nguyen, MD, Zahava Ohana, PharmD
Drug Profiles/Updates
Ipilimumab: Unique Responses, Toxicities, and Recommendations for the Use of the First Anti–CTLA-4 Therapy in Patients with Melanoma
Michael K.K. Wong, MD, PhD, FRCPC, Anthony Jarkowski III, PharmD, BCOP
Drug Profiles/Updates
A Review of PARP Inhibitors in Clinical Development
Sarah Hopps, PharmD, Carla D. Kurkjian, MD, Shubham Pant, MD
Drug Profiles/Updates
Reversible Posterior Leukoencephalopathy Syndrome Secondary to Bevacizumab
Diana Pinto, PharmD, William Kernan, PharmD, BCPS, James Hoffman, MD, Mohammed Ibrahim, PharmD, CRPH, BCOP, BCPS, Bruno Bastos, MD
Page 4 of 4
Results 31 - 40 of 40